^
    9d
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=13, Terminated, Zhejiang Doer Biologics Co., Ltd. | N=94 --> 13 | Trial completion date: Jun 2025 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Dec 2025; This trial was terminated voluntarily by the Sponsor for reasons related to its corporate strategic development, with no safety concerns or efficacy signals related to the investigational product identified.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    DR30303
    over1year
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    DR30303
    2years
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Sep 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    DR30303
    over3years
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd.
    New P1 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    DR30303